Low dose combination polydiuretic therapy — Competitive Intelligence Brief

Low dose combination polydiuretic therapy (Low dose combination polydiuretic therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Diuretic combination. Area: Cardiovascular.

marketed Diuretic combination Cardiovascular Small molecule

Target snapshot

Low dose combination polydiuretic therapy (Low dose combination polydiuretic therapy) — The George Institute. A fixed-dose combination of multiple diuretics at reduced individual doses that work synergistically to reduce blood pressure and fluid retention while minimizing electrolyte disturbances.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low dose combination polydiuretic therapy TARGET	Low dose combination polydiuretic therapy	The George Institute	marketed	Diuretic combination
losartan and HCTZ	losartan and HCTZ	InVasc Therapeutics, Inc.	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (losartan); sodium-chloride cotransporter (HCTZ)
Aliskiren Hydrochlorothiazide	Aliskiren Hydrochlorothiazide	Novartis	marketed	Direct renin inhibitor / thiazide diuretic combination	Renin; sodium-chloride cotransporter (NCCT)
Perindopril plus Hydrochlorothiazide	Perindopril plus Hydrochlorothiazide	University of Abuja	marketed	ACE inhibitor plus thiazide diuretic combination	Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter in the distal convoluted tubule
Micardis plus 80/12.5	Micardis plus 80/12.5	Heart Care Foundation	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
Perindopril + amlodipine + if necessary, hydrochlorothiazide	Perindopril + amlodipine + if necessary, hydrochlorothiazide	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	ACE inhibitor + calcium channel blocker + thiazide diuretic combination	Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter
Atenolol Thiazide	Atenolol Thiazide	Institut de Recherches Cliniques de Montreal	marketed	Beta-blocker and thiazide diuretic combination	Beta-1 adrenergic receptor; sodium-chloride cotransporter (thiazide-sensitive)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Diuretic combination class)

1. The George Institute · 1 drug in this class